SCM
ARRY

Stonebridge Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Stonebridge Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,850
Closed -$95K – 140
2016
Q4 		$95K Hold
10,850
– – 0.04% 123
2016
Q3 		$73K Hold
10,850
– – 0.03% 122
2016
Q2 		$39K Sell
10,850
-41,075
-79% -$134K 0.02% 126
2016
Q1 		$153K Buy
+51,925
New +$156K 0.07% 147

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Stonebridge Capital Management's ARRY Position: Q1 2017 in Review

Stonebridge Capital Management sold out of Array Biopharma Inc (ARRY) in Q1 2017, closing a stake of 10,850 shares — an estimated $95K sold.

Stonebridge Capital Management first reported a position in ARRY in Q1 2016 and held it in 4 quarters. The position peaked at $153K in Q1 2016. 187 funds tracked by Wall St. Rank hold ARRY as of Q1 2017.

  • Stonebridge Capital Management reported no remaining Array Biopharma Inc position as of Q1 2017 after selling out during the quarter.
  • Stonebridge Capital Management sold 10,850 Array Biopharma Inc shares in Q1 2017, an estimated $95K.
  • Stonebridge Capital Management first reported a position in Array Biopharma Inc in Q1 2016 and held it in 4 quarters.
  • Stonebridge Capital Management's Array Biopharma Inc position peaked at $153K in Q1 2016.
  • 187 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2017.

Based on Stonebridge Capital Management's 13F filing for Q1 2017, filed 26 Apr 2017.